The effects of thalidomide on chemotactic migration of multiple myeloma cell lines

International Journal of Laboratory Hematology

Volumn 30, Issue 3, 2008, Pages 220-229

  Fuchida, S I ^a   Shimazaki, C ^a   Hirai, H ^a   Akamatsu, S ^a   Yamada, N ^a   Uchida, R ^a   Okano, A ^a   Okamoto, M ^a   Inaba, T ^a   Taniwaki, M ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chemotactic migration; Multiple myeloma; Stromal cell derived factor 1 alpha; Thalidomide

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DEXAMETHASONE; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE;

ARTICLE; CELL GROWTH; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE; CHEMOKINE CXCL12; CHEMOTAXIS; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, CHEMOKINE; THALIDOMIDE;

EID: 43549112348     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00948.x     Document Type: Article

References (28)

1. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U.K., Pitsillides C.M., Spencer J.A., Kimlinger T., Ghobrial J.M., Jia X., Lu G., Timm M., Kumar A., Cote D., Veilleux I., Hedin K.E., Roodman G.D., Witzig T.E., Kung A.L., Hideshima T., Anderson K.C., Lin C.P. Ghobrial I.M. (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCRL-12) dependent migration and homing in multiple myeloma. Blood 109, 2708 2717.
2. Baggiolini M. (1998) Chemokines and leukocyte traffic. Nature 392, 565 568.
3. Bleul C.C., Schultze J.L. Springer T.A. (1998) B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. Journal of Experimental Medicine 187, 753 762.
4. Broek I.V., Asosingh K., Vanderkerken K., Straetmans N., Camp B.V. Riet I.V. (2003) Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. British Journal of Cancer 88, 855 862.
5. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C. Schall T.J. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. Journal of Experimental Medicine 203, 2201 2213.
6. D'Apuzzo M., Rolink A., Loetscher M., Hoxie J.A., Clark-Lewis I., Melchers F., Baggiolini M. Moser B. (1997) The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. European Journal of Immunology 27, 1788 1793.
7. Durig J., Schmucker U. Duhrsen U. (2001) Differential expression of chemokine receptors in B cell malignancies. Leukemia 15, 752 756.
8. Figg W.D., Raje S., Bauer K.S., Tompkins A., Venzon D., Bergan R., Chen A., Hamilton M., Pluda J. Reed E. (1999) Pharmacokinetics of thalidomide in an elderly prostate cancer population. Journal of Pharmacological Sciences 88, 121 125.
9. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., Treon S.P., Lin B., Schlossman R.L., Richardson P., Muller G., Stirling D.I. Anderson K.C. (2000) Talidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96, 2943 2950.
10. Hideshima T., Richardson P. Anderson K.C. (2003) Novel therapeutic approaches for multiple myeloma. Immunological Reviews 194, 164 176.
11. Honczarenko M., Douglas R.S., Mathias C., Lee B., Ratajczak M.Z. Silberstein L.E. (1999) SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells. Blood 94, 2990 2998.
12. Kanellis J., Kandane R.K, Etemadmoghadam D., Fraser S.A., Mount P.F. Power D. A. (2006) Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. Immunology and Cell Biology 84, 6 12.
13. Kyle R.A. Rajkumar S.V. (2004) Multiple myeloma. New England Journal of Medicine 351, 1860 1873.
14. Mellado M., Rodriguez-Frade J.M., Aragay A., del Real G., Martin A.M., Vila-Coro A.J., Serrano A., Mayor F., Jr. Martinez A.C. (1998) The chemokine monocyte chemotactic protein 1 triggers Janus Kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. Journal of Immunology 161, 805 813.
15. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., Munshi N.C., Treon S.P. Anderson K.C. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99, 4525 4530.
16. Möller C., Strömberg T., Juremalm M., Nilsson K. Nilsson G. (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17, 203 210.
17. Ochiai N., Yamada N., Uchida R., Fuchida S., Okano A., Hatsuse M., Okamoto M., Ashihara E. Shimazaki C. (2005) Combination therapy with thalidomide, incadronate and dexamethasone (TID) for relapsed or refractory multiple myeloma. International Journal of Hematology 82, 243 247.
18. Parmo-Cabañas M., Bartolomé R.A., Wright N., Hidalgo A., Drager A.M. Teixidó J. (2004) Integrinα4β1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Experimental Cell Research 294, 571 580.
19. Podar K., Shringarpure R, Tai Y.T, Simoncini M., Sattler M., Ishitsuka K., Richardson P.G., Hideshima T., Chauhan D. Anderson K. (2004) Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Research 64, 7500 7506.
20. Richardson P., Hideshima T. Anderson K. (2002) Thalidomide: emerging role in cancer medicine. Annual Review of Medicine 53, 629 657.
21. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J. Murphy W.J. (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96, 34 40.
22. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A. Kaplan G. (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Journal of Experimental Medicine 173, 699 703.
23. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeldis J. Barlogie B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine 341, 1565 1571.
24. Smith M.R., Xie T., Joshi I. Schilder R.J. (1998) Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. British Journal of Haematology 102, 1090 1097.
25. Stirling D.I. (2000) Pharmacology of thalidomide. Seminars in Hematology 37 (Suppl. 3 5 14.
26. Tseng S., Pak G., Washenik K., Pomeranz M.K. Shupack J.L. (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Journal of the American Academy of Dermatology 35, 969 979.
27. Wehrli N., Legler D.F., Finke D., Toellner K.M., Loetscher P., Baggiolini M., MacLennan I.C.M. Acha-Orbea H. (2001) Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. European Journal of Immunology 31, 609 616.
28. Witzig T.E. (1999) The role of adhesion receptors in the pathogenesis of multiple myeloma. Hematology Oncology Clinics of North America 13, 1127 1143.